Skip to content

SurfScreen Pilot for TIGIT

The Challenge 

  • Screening for antibodies that block the interaction between ligand and receptor
  • Validating blocking with pseudovirus neutralization assays

The Single Cell Solution

  • Develop a blocking assay that has a high correlation with neutralizing the virus
  • Set up the assay in-line during discovery to save downstream time

Highlights

  • Screening for antibodies that block the interaction between ligand and receptor
  • Validated blocking with pseudovirus neutralization assays

Problem: Taking on the Challenge

Demonstrate ability to screen antibodies against membrane targets, a high-value capability in antibody discovery.

Incorporate SurfScreen and SimulScreen together

Solution: Finding a Better Way

SurfScreen is a new screening mode in AbTheneum™ capable of addressing membrane-bound targets. We align 2 picowell devices together – yes, all 90,000+ wells – to allow antibodies to interact with the membrane-bound target on the cells. Then, we separate the 2 devices, detect and image the bound antibodies. 

 

lasma cells were isolated from TIGIT-immunized wild-type mice and loaded onto our picoliter device

In this case study, plasma cells were isolated from TIGIT-immunized wild-type mice and loaded onto our picoliter device.

On a separate picoliter device, we overloaded TIGIT-expressing cells. We aligned and incubated the 2 devices together to allow the antibodies secreted from the plasma cells to interact with the TIGIT-expressing cells.

Once incubation was complete, we separated the 2 devices and imaged the TIGIT-expressing cells to detect antibodies bound to the membrane using a fluorescent secondary antibody.

Overloaded TIGIT expressing cells in brightfield

Overloaded TIGIT expressing cells in brightfield

Overloaded TIGIT-expressing cells in fluorescent channel, showing some wells have mouse antibody bound to the membrane.

Overloaded TIGIT-expressing cells in fluorescent channel, showing some wells have mouse antibody bound to the membrane.

On a cell-by-cell basis, we see some wells had cell-binding antibodies that were cross-reactive, some wells had cross-reactive antibodies that don’t bind cells, and some cell-binding antibodies are not cross-reactive.

TIGIT-expressing cells in brightfield, cell-binding antibodies detected on TIGIT-expressing cells, SimulScreen data from captured antibodies showing binding to human TIGIT, and SimulScreen data from captured antibodies showing binding to cynomolgus TIGIT.

Data output from monoclonal antibodies from a single picowell. Each picowell generated a set of 4 images showing TIGIT-expressing cells in brightfield, cell-binding antibodies detected on TIGIT-expressing cells, SimulScreen data from captured antibodies showing binding to human TIGIT, and SimulScreen data from captured antibodies showing binding to cynomolgus TIGIT.

This project used a recombinant extracellular domain (ECD) of TIGIT to immunize the mice, and it is common that antibodies derived from that type of immunogen do not always bind to the cell membrane. We do see examples of that, and we see examples of cell-binders that are not cross-reactive.

Outcomes: Moving the Campaign Ahead

  • SurfScreen can screen antibodies against targets expressed on cells. 

  • SurfScreen could be applied to complex multipass transmembrane targets such as ion channels and G-protein coupled receptors (GPCRs)

  • SurfScreen can be run in parallel to SimulScreen assays, if there are recombinant versions of the protein that can be used

  • Sequence capture for SurfScreen is the same as all other AbTheneum projects, due to keeping antibodies separate from antibody-secreting cells

Related Articles